Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jan 15;272(2):135.
doi: 10.1007/s00415-024-12868-2.

Cerebral vasculitis related to neurosarcoidosis: a case series and systematic literature review

Affiliations
Case Reports

Cerebral vasculitis related to neurosarcoidosis: a case series and systematic literature review

Jan K Focke et al. J Neurol. .

Abstract

Cerebral vasculitis is a rare but severe manifestation of neurosarcoidosis (NS) that has received little attention. The aim of the present study was to characterize clinical and diagnostic features as well as potential treatment strategies of cerebral vasculitis related to NS. We assessed 29 patients with cerebral vasculitis related to NS (15 female, mean age at time of diagnosis 45 years, SD = 11.85) among these were four new cases from our hospital records and 25 previously published cases from a systematic literature review. The demographic, clinical, and diagnostic features of those 29 patients with cerebral vasculitis related to NS were compared with a group of 73 NS patients without vasculitic involvement (37 female, mean age at time of diagnosis 47 years, SD = 14.79). Neurologic deficits and MRI abnormalities were significantly more frequent in cerebral vasculitis related to NS than in NS without vasculitic involvement. Patients with cerebral vasculitis related to NS significantly more often presented with headache, motor symptoms, and cognitive and/or behavioral changes. Non-neurologic manifestations of sarcoidosis did not significantly differ in character or frequency between both groups. Glucocorticoids in combination with methotrexate, cyclophosphamide, or infliximab were the most frequently used treatment strategies in cerebral vasculitis related to NS. Within the complex diagnostic work-up that is required in cerebral vasculitis related to NS sufficient angiographic imaging as digital subtraction angiography or MRI vessel wall imaging and tissue biopsy are of particular significance as they can detect vascular changes caused by inflammatory processes.

Keywords: Cerebral ischemia; Intracranial hemorrhage; Neurosarcoidosis; Sarcoidosis; Stroke; Vasculitis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: Roland Veltkamp reports grants from Boehringer Ingelheim; grants from Medtronic; grants from Daiichi Sankyo Company; compensation from Portola Pharmaceuticals for end point review committee services; compensation from Bristol Myers Squibb for consultant services; grants from Bayer; grants from Bristol Myers Squibb; compensation from Daiichi Sankyo Company for consultant services; compensation from AstraZeneca for consultant services; and compensation from Javelin Ventures for consultant services. All other authors report no conflicts. Ethical approval: Due to its retrospective nature this study was conducted only on already existing data. The study was conducted in accordance with local ethical requirements.

Figures

Fig. 1
Fig. 1
Flow chart of the literature review process
Fig. 2
Fig. 2
Neuroradiological characteristics of 4 patients with cerebral vasculitis related to neurosarcoidosis a MRI with leptomeningeal gadolinium enhancement in patient 1 from Table 5. b MRI with gliosis of brainstem in patient 1 from Table 5. c Angiogram with one microaneurysm of a pontine perforator artery in patient 1 from Table 5. d Angiogram with one microaneurysm of a pontine perforator artery in patient 4 from Table 5. e Angiogram with bilateral multiple caliber irregularities in patient 2 from Table 5. f Angiogram with moyamoya-like vasculitis in patient 3 from Table 5

References

    1. Valeyre D, Prasse A, Nunes H et al (2014) Sarcoidosis. The Lancet 383:1155–1167. 10.1016/S0140-6736(13)60680-7 - PubMed
    1. Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 357:2153–2165. 10.1056/NEJMra071714 - PubMed
    1. Polverino F, Balestro E, Spagnolo P (2020) Clinical presentations, pathogenesis, and therapy of sarcoidosis: state of the art. J Clin Med 9:2363. 10.3390/jcm9082363 - PMC - PubMed
    1. Ungprasert P, Carmona EM, Utz JP et al (2016) Epidemiology of sarcoidosis 1946–2013: a population based study. Mayo Clin Proc 91:183–188. 10.1016/j.mayocp.2015.10.024 - PMC - PubMed
    1. Fritz D, van de Beek D, Brouwer MC (2016) Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol 16:220. 10.1186/s12883-016-0741-x - PMC - PubMed

MeSH terms

Supplementary concepts

LinkOut - more resources